Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus

US12226471B2 · kind B2 · utility

Assignees

• The Trustees of the University of Pennsylvania · US
• THE JOHNS HOPKINS UNIVERSITY · US
• VANDERBILT UNIVERSITY · US

Inventors

• Drew Weissman · Wynnebrook Manor, US
• George M. Shaw · Birmingham, US
• Justin R. Bailey · Timonium, US
• Stuart C. Ray · Timonium, US
• James E. Crowe, Jr. · Nashville, US
• Andrew Flyak · Nashville, US

Key dates

• Filing date: May 1, 2023
• Grant date: Feb 18, 2025
• Expiry date: May 1, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/24234
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.